Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Microscope in a BioEscalator Lab

News

MediMabBio signs MOU with PDC*line Pharma to collaborate on cancer immunotherapy

MediMabBio has announced a new memorandum of understanding (MOU) with PDCline Pharma. This collaboration aims to explore the synergy between MediMabBio's MMB101/MFA011 and PDC*line Pharma’s plasmacytoid dendritic cell (PDC) cancer vaccines to revolutionise cancer treatment. Together, their promising drug candidates, targeting TIGIT and other immuno-oncology pathways, would enhance the efficacy of PDC cancer vaccines. By leveraging PDC*line Pharma’s expertise, MediMabBio aims to boost the efficacy of its therapies and explore innovative treatment strategies.

Upcoming Events

Innovation Roadshow: OXFORD

Tuesday, 21 May 2024, 10am to 11.30am

Join Monika Dabrowska, the Director of Innovaction Global and a Monitoring Service Provider at Innovate UK, for an exclusive Innovation Roadshow workshop where she will share valuable tools and three key insights to look at when writing grant applications.

BioEscalator Team
Photograph of the BioEscalator building and adjoining carpark, taken from the top of the Kennedy building © BioEscalator Oxford